TNFRSF4 and neoplasm: HVJ-E + OX40 antibody (HVJ-E/OX40 antibody) significantly suppressed tumor growth at both the target (p < 0.0001) and non-target (p < 0.0006) lesions, while administration of OX40 antibody alone did not suppress tumor growth in either lesion (p = 0.5289 and p > 0.2746, respectively; Figure 2C).